Hind Rafei

18PUBLICATIONS
95CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapyReaction engineering (excl. nuclear reactions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jul 02, 2026
A guide to CAR T cell therapies: development, current status and future prospects.

|Jun 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur

|Jun 04, 2025
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells.

Hind Rafei, Rafet Basar, Sunil Acharya

|Apr 04, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur

|Dec 02, 2024
Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer.

Hind Rafei, Katayoun Rezvani

|Sep 11, 2024
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.

Bijender Kumar, Anand Singh, Rafet Basar

Pageof 3

Frequent Collaborators

10 joint publications

Katayoun Rezvani

9 joint publications

May Daher

8 joint publications

Ye Li

6 joint publications

Mecit Kaplan